- Home
- SXTP vs XBIO Comparison
SXTP vs XBIO Comparison
Compare SXTP & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXTP
- XBIO
- Stock Information
- Founded
- SXTP 2010
- XBIO N/A
- Country
- SXTP United States
- XBIO United States
- Employees
- SXTP N/A
- XBIO N/A
- Industry
- SXTP Biotechnology: Pharmaceutical Preparations
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- SXTP Health Care
- XBIO Health Care
- Exchange
- SXTP Nasdaq
- XBIO Nasdaq
- Market Cap
- SXTP 4.3M
- XBIO 4.2M
- IPO Year
- SXTP 2023
- XBIO N/A
- Fundamental
- Price
- SXTP $2.32
- XBIO $3.53
- Analyst Decision
- SXTP Buy
- XBIO Hold
- Analyst Count
- SXTP 2
- XBIO 1
- Target Price
- SXTP $7.00
- XBIO N/A
- AVG Volume (30 Days)
- SXTP 324.9K
- XBIO 169.6K
- Earning Date
- SXTP 08-13-2025
- XBIO 08-12-2025
- Dividend Yield
- SXTP N/A
- XBIO N/A
- EPS Growth
- SXTP N/A
- XBIO N/A
- EPS
- SXTP N/A
- XBIO N/A
- Revenue
- SXTP $802,323.00
- XBIO $2,582,728.00
- Revenue This Year
- SXTP $95.50
- XBIO $14.23
- Revenue Next Year
- SXTP $80.78
- XBIO $7.14
- P/E Ratio
- SXTP N/A
- XBIO N/A
- Revenue Growth
- SXTP 118.37
- XBIO 5.63
- 52 Week Low
- SXTP $1.41
- XBIO $2.20
- 52 Week High
- SXTP $35.99
- XBIO $5.27
- Technical
- Relative Strength Index (RSI)
- SXTP 50.64
- XBIO 58.63
- Support Level
- SXTP $1.91
- XBIO $2.65
- Resistance Level
- SXTP $2.55
- XBIO $5.27
- Average True Range (ATR)
- SXTP 0.24
- XBIO 0.45
- MACD
- SXTP -0.00
- XBIO 0.09
- Stochastic Oscillator
- SXTP 46.09
- XBIO 33.61
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.